Ionis Pharmaceuticals (IONS) PT Lowered to $55 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Ionis Pharmaceuticals (IONS) PT Lowered to $68 at Laidlaw
October 18, 2021 7:53 AM EDTLaidlaw analyst Yale Jen lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $78.00) while maintaining a Buy rating.
Tofersen in SOD1-ALS VALOR Trial Failed to Meet Primary Endpoint but Substantial Knowledge Learned... More